Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
Drug-drug interactions in pharmaceutical development [[electronic resource] /] / edited by Albert P. Li
| Drug-drug interactions in pharmaceutical development [[electronic resource] /] / edited by Albert P. Li |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-interscience, c2008 |
| Descrizione fisica | 1 online resource (261 p.) |
| Disciplina |
615.7045
615/.7045 |
| Altri autori (Persone) | LiA. P |
| Collana | Wiley series in drug discovery and development |
| Soggetto topico |
Drug interactions
Drug development |
| ISBN |
1-282-02206-7
9786612022067 0-470-18792-1 0-470-18791-3 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DRUG-DRUG INTERACTIONS IN PHARMACEUTICAL DEVELOPMENT; CONTENTS; Preface; Contributors; 1 In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice; 1.1 Introduction; 1.2 Mechanisms of Adverse Drug-Drug Interactions; 1.2.1 Pharmacological Interactions; 1.2.2 Pharmacokinetic Interactions; 1.3 Drug Metabolism; 1.3.1 Phase I Oxidation; 1.3.2 Phase II Conjugation; 1.4 CYP Isoforms; 1.5 Human In Vitro Experimental Systems for Drug Metabolism; 1.5.1 Hepatocytes; 1.5.2 Liver Postmitochondrial Supernatant (PMS); 1.5.3 Human Liver Microsomes; 1.5.4 Recombinant P450 Isoforms (rCYP)
1.5.5 Cytosol1.6 Mechanisms of Metabolic Drug-Drug Interactions; 1.7 Mechanism-Based Approach for Evaluation of Drug-Drug Interaction Potential; 1.7.1 Metabolic Phenotyping; 1.7.2 Evaluation of Inhibitory Potential for Drug-Metabolizing Enzymes; 1.7.3 Induction Potential for Drug-Metabolizing Enzymes; 1.8 Experimental Approaches for In Vitro Evaluation of Drug-Drug Interaction Potential; 1.8.1 Study 1: Metabolic Phenotyping 1-Metabolite Identification; 1.8.2 Study 2: Metabolic Phenotyping 2-Identification of Major Metabolic Pathways 1.8.3 Study 3: Metabolic Phenotyping 3-Identification of P450 Isoform Pathways (P450 Phenotyping)1.8.4 Study 4: CYP Inhibitory Potential; 1.8.5 Study 5: Enzyme Induction Potential; 1.8.6 Study 6: In Vitro Empirical Drug-Drug Interactions; 1.9 Data Interpretation; 1.9.1 Pathway Evaluation; 1.9.2 P450 Inhibition; 1.9.3 P450 Induction; 1.10 Conclusion; References; 2 In Vitro Approaches to Anticipating Clinical Drug Interactions; 2.1 In Vitro Systems for Human CYP450 Metabolism; 2.1.1 Incubation Buffer (pH and Ionic Strength); 2.1.2 MgCl(2) and Cytochrome b(5); 2.1.3 Nonspecific Binding 2.1.4 Organic Solvents and Excipients2.2 Analysis of Data from In Vitro Systems; 2.2.1 Linear Transformation of Michaelis-Menten Equation (Lineweaver-Burk and Eadie-Hofstee); 2.2.2 Nonlinear Regression Analysis of Hyperbolic Kinetic Data; 2.2.3 Consideration of Non-Michaelis-Menten Kinetics; 2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance; 2.3.1 Calculation of In Vitro (Predicted) Hepatic Clearance; 2.3.2 Comparison of In Vitro (Predicted) with In Vivo Hepatic Clearance; 2.4 Use of In Vitro Kinetic Data to Predict Drug-Drug Interactions 2.4.1 Choice of Probe Substrates for Inhibition Studies2.4.2 Determining the Mechanism of CYP450 Inhibition; 2.4.3 Prediction of In Vivo Drug-Drug Inhibition Interactions from In Vitro Data; 2.5 Consideration of Non-CYP Enzymatic Systems; 2.5.1 Flavin-Containing Monooxygenase (FMO); 2.5.2 UDP-glucuronosyltransferase (UGT); 2.5.3 Sulfotransferase (SULT); 2.5.4 N-Acetyltransferase (NAT); 2.5.5 Methyltransferase; 2.5.6 Epoxidase Hydrolase; 2.5.7 Aldehyde Oxidase and Dehydrogenase; 2.5.8 Glutathione-S-transferase (GST); 2.6 Summary; 2.7 Acknowledgments; References 3 Inhibition of Drug-Metabolizing Enzymes and Drug-Drug Interactions in Drug Discovery and Development |
| Record Nr. | UNINA-9910143982103321 |
| Hoboken, N.J., : Wiley-interscience, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug-drug interactions in pharmaceutical development / / edited by Albert P. Li
| Drug-drug interactions in pharmaceutical development / / edited by Albert P. Li |
| Edizione | [1st ed.] |
| Pubbl/distr/stampa | Hoboken, N.J., : Wiley-interscience, c2008 |
| Descrizione fisica | 1 online resource (261 p.) |
| Disciplina |
615.7045
615/.7045 |
| Altri autori (Persone) | LiA. P |
| Collana | Wiley series in drug discovery and development |
| Soggetto topico |
Drug interactions
Drug development |
| ISBN |
1-282-02206-7
9786612022067 0-470-18792-1 0-470-18791-3 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
DRUG-DRUG INTERACTIONS IN PHARMACEUTICAL DEVELOPMENT; CONTENTS; Preface; Contributors; 1 In Vitro Evaluation of Metabolic Drug-Drug Interactions: Concepts and Practice; 1.1 Introduction; 1.2 Mechanisms of Adverse Drug-Drug Interactions; 1.2.1 Pharmacological Interactions; 1.2.2 Pharmacokinetic Interactions; 1.3 Drug Metabolism; 1.3.1 Phase I Oxidation; 1.3.2 Phase II Conjugation; 1.4 CYP Isoforms; 1.5 Human In Vitro Experimental Systems for Drug Metabolism; 1.5.1 Hepatocytes; 1.5.2 Liver Postmitochondrial Supernatant (PMS); 1.5.3 Human Liver Microsomes; 1.5.4 Recombinant P450 Isoforms (rCYP)
1.5.5 Cytosol1.6 Mechanisms of Metabolic Drug-Drug Interactions; 1.7 Mechanism-Based Approach for Evaluation of Drug-Drug Interaction Potential; 1.7.1 Metabolic Phenotyping; 1.7.2 Evaluation of Inhibitory Potential for Drug-Metabolizing Enzymes; 1.7.3 Induction Potential for Drug-Metabolizing Enzymes; 1.8 Experimental Approaches for In Vitro Evaluation of Drug-Drug Interaction Potential; 1.8.1 Study 1: Metabolic Phenotyping 1-Metabolite Identification; 1.8.2 Study 2: Metabolic Phenotyping 2-Identification of Major Metabolic Pathways 1.8.3 Study 3: Metabolic Phenotyping 3-Identification of P450 Isoform Pathways (P450 Phenotyping)1.8.4 Study 4: CYP Inhibitory Potential; 1.8.5 Study 5: Enzyme Induction Potential; 1.8.6 Study 6: In Vitro Empirical Drug-Drug Interactions; 1.9 Data Interpretation; 1.9.1 Pathway Evaluation; 1.9.2 P450 Inhibition; 1.9.3 P450 Induction; 1.10 Conclusion; References; 2 In Vitro Approaches to Anticipating Clinical Drug Interactions; 2.1 In Vitro Systems for Human CYP450 Metabolism; 2.1.1 Incubation Buffer (pH and Ionic Strength); 2.1.2 MgCl(2) and Cytochrome b(5); 2.1.3 Nonspecific Binding 2.1.4 Organic Solvents and Excipients2.2 Analysis of Data from In Vitro Systems; 2.2.1 Linear Transformation of Michaelis-Menten Equation (Lineweaver-Burk and Eadie-Hofstee); 2.2.2 Nonlinear Regression Analysis of Hyperbolic Kinetic Data; 2.2.3 Consideration of Non-Michaelis-Menten Kinetics; 2.3 Use of In Vitro Kinetic Data to Predict In Vivo Clearance; 2.3.1 Calculation of In Vitro (Predicted) Hepatic Clearance; 2.3.2 Comparison of In Vitro (Predicted) with In Vivo Hepatic Clearance; 2.4 Use of In Vitro Kinetic Data to Predict Drug-Drug Interactions 2.4.1 Choice of Probe Substrates for Inhibition Studies2.4.2 Determining the Mechanism of CYP450 Inhibition; 2.4.3 Prediction of In Vivo Drug-Drug Inhibition Interactions from In Vitro Data; 2.5 Consideration of Non-CYP Enzymatic Systems; 2.5.1 Flavin-Containing Monooxygenase (FMO); 2.5.2 UDP-glucuronosyltransferase (UGT); 2.5.3 Sulfotransferase (SULT); 2.5.4 N-Acetyltransferase (NAT); 2.5.5 Methyltransferase; 2.5.6 Epoxidase Hydrolase; 2.5.7 Aldehyde Oxidase and Dehydrogenase; 2.5.8 Glutathione-S-transferase (GST); 2.6 Summary; 2.7 Acknowledgments; References 3 Inhibition of Drug-Metabolizing Enzymes and Drug-Drug Interactions in Drug Discovery and Development |
| Record Nr. | UNINA-9910818381003321 |
| Hoboken, N.J., : Wiley-interscience, c2008 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Drug-induced ocular side effects / Frederick T. Fraunfelder, Frederick W. Fraunfelder, Wiley A. Chambers ; associate editor Bree Jensvold-Vetsch
| Drug-induced ocular side effects / Frederick T. Fraunfelder, Frederick W. Fraunfelder, Wiley A. Chambers ; associate editor Bree Jensvold-Vetsch |
| Autore | Fraunfelder, Frederick T. |
| Edizione | [7th ed.] |
| Pubbl/distr/stampa | New York ; Philadelphia : Elsevier Saunders, 2015 |
| Descrizione fisica | xi, 411 p. : ill. ; 29 cm |
| Disciplina | 615/.78 |
| Altri autori (Persone) |
Fraunfelder, Frederick W.
Chambers, Wiley A. Jensvold Vetsch, Bree |
| Soggetto topico |
Ocular pharmacology
Drugs - Side effects Drug interactions |
| ISBN | 9780323319843 |
| Classificazione |
LC RE994
617.7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISALENTO-991002814899707536 |
Fraunfelder, Frederick T.
|
||
| New York ; Philadelphia : Elsevier Saunders, 2015 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. del Salento | ||
| ||
Infectious Diseases and Your Health [[electronic resource] /] / edited by Prati Pal Singh
| Infectious Diseases and Your Health [[electronic resource] /] / edited by Prati Pal Singh |
| Edizione | [1st ed. 2018.] |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2018 |
| Descrizione fisica | 1 online resource (424 pages) |
| Disciplina | 616.9 |
| Soggetto topico |
Medical parasitology
Emerging infectious diseases Drug interactions Parasitology Infectious Diseases Drug Resistance Public Health |
| ISBN | 981-13-1577-9 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto | Part 1: Parasitic infections -- Satranidazole and my pharmaceutical research odyssey: a success story -- Amoebiasis revisited -- Cerebral malaria: players in the pathogenic mechanism and treatment strategies -- Role of white blood cells in immunopathogenesis of cerebral malaria -- Chemotherapy and experimental models of visceral leishmaniasis -- Human trichomoniasis -- Taeniasis and neurocysticercosis: emerging public health problems -- Helminth parasites: the cause of distress and diseases -- Neglected tropical diseases: a biosocial perspective. Part 2: Bacterial infections -- Autophagy: a potential anti-bacterial therapeutic target -- Antibiotics and antimicrobial resistance -- Nontuberculous mycobacteria: an update on infections caused, laboratory identification and their treatment -- Drugs under pre-clinical and clinical testing for the treatment of infections caused due to Staphylococcus aureus: an update -- Recurrent vulvovaginal infections: etiology, diagnosis, treatment and management -- Enterococci as nosocomial pathogen -- Dietary antioxidants and infectious diseases -- Probiotic lactobacilli, infection and immunomodulation -- Part 3: Viral infections -- HIV-AIDS: an unconquered immune-war -- Chikungunya fever: where are we today? - Epigenetics and infectious pathogens: interactions, ploy and perspectives -- Part 4: Fungal infections -- An update on sexually transmitted infections: an Indian context -- Candida: friend and foe of humans. |
| Record Nr. | UNINA-9910298427603321 |
| Singapore : , : Springer Singapore : , : Imprint : Springer, , 2018 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Interacciones de medicamentos [[electronic resource] ] : lo que usted debe saber / / Council on Family Health
| Interacciones de medicamentos [[electronic resource] ] : lo que usted debe saber / / Council on Family Health |
| Pubbl/distr/stampa | [Rockville, Md.?] : , : Food and Drug Administration, , [2002] |
| Descrizione fisica | 9 unnumbered pages : digital, PDF file |
| Soggetto topico | Drug interactions |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | spa |
| Altri titoli varianti | Interacciones de medicamentos |
| Record Nr. | UNINA-9910698782903321 |
| [Rockville, Md.?] : , : Food and Drug Administration, , [2002] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
The medical letter on drugs and therapeutics
| The medical letter on drugs and therapeutics |
| Pubbl/distr/stampa | New Rochelle, NY, : Medical Letter, Inc |
| Disciplina | 615 |
| Soggetto topico |
Drug interactions
Drugs Pharmacology Chemotherapy Pharmaceutical Preparations Therapeutics |
| Soggetto genere / forma |
Periodical
Periodicals. |
| ISSN | 1523-2859 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | Medical letter |
| Record Nr. | UNISA-996518461503316 |
| New Rochelle, NY, : Medical Letter, Inc | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Multi-drug resistance in cancer : mechanism and treatment strategies / / edited by Rishabha Malviya, Arun Kumar Singh, and Deepika Yadav
| Multi-drug resistance in cancer : mechanism and treatment strategies / / edited by Rishabha Malviya, Arun Kumar Singh, and Deepika Yadav |
| Pubbl/distr/stampa | Hoboken, NJ : , : John Wiley & Sons, , [2023] |
| Descrizione fisica | 1 online resource (216 pages) |
| Disciplina | 614.5999 |
| Soggetto topico |
Multidrug resistance
Drug resistance in cancer cells Drug interactions |
| Soggetto non controllato |
Pharmacology
Medical |
| ISBN |
1-394-20986-X
1-394-20985-1 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover -- Title Page -- Copyright Page -- Contents -- Foreword -- Preface -- Acknowledgment -- Chapter 1 Multi-Drug Rmesistance in Cancer: Understanding of Treatment Strategies -- 1.1 Introduction -- 1.2 Both Congenital and Developed Resistance to Drugs -- 1.2.1 Intrinsic Resistance -- 1.2.2 Acquired Resistance -- 1.3 Drug-Resistance Mechanisms -- 1.3.1 Increased Efflux of Drugs -- 1.3.2 Impact on Medication Target -- 1.3.3 Improved DNA-Damage Repair -- 1.4 Senescence Escape -- 1.5 Epigenetic Alterations -- 1.6 Tumor Heterogeneity -- 1.7 Tumor Microenvironment -- 1.8 Epithelial to Mesenchymal Transition -- 1.9 Conclusion -- References -- Chapter 2 Understanding Different Mechanisms Involved in Cancer Drug Resistance: Proposing Novel Strategies to Overcome MDR -- 2.1 Introduction -- 2.2 Drug Resistance: Internal and External Variables -- 2.2.1 Phenotypic Variation of Tumors -- 2.2.2 Tumor Microenvironment -- 2.2.3 Cancer Stem Cells -- 2.2.4 Inactivation of the Anticancer Drugs -- 2.2.5 Multi-Drug Resistance -- 2.2.6 Increasing the Release of Drugs Outside the Cell -- 2.2.7 Reducing the Absorption of the Drugs -- 2.2.8 Inhibition of Cell Death (Apoptosis Pathway Blocking) -- 2.3 Improving the Pharmacokinetics -- 2.4 Changing the Aim of the Chemotherapy Agents -- 2.5 Improving the DNA Repair Process -- 2.5.1 Augmentation of a Gene -- 2.5.2 Epigenetic Altering Caused Drug Resistance -- 2.6 MicroRNA in Cancer Drug Resistance -- 2.7 Conclusion -- References -- Chapter 3 Molecular Mechanism of Multi-Drug Resistant Cancer Cells -- 3.1 Introduction -- 3.2 Types of Drug Resistance -- 3.3 Mechanisms of Drug Resistance -- 3.3.1 Drug Efflux via ABC Transporters -- 3.3.2 Permeability Glycoprotein/MDR-1 -- 3.3.3 Multi-Drug Resistance Protein -- 3.3.4 Breast Cancer Resistance Protein -- 3.4 Reduction in Drug Activity and Cellular Absorption.
3.5 Instability in the Genome and Medication Resistance -- 3.5.1 Mutation and Medication Target Alteration -- 3.5.2 Restoration of DNA Integrity -- 3.5.3 Resistant Genes and Epigenetic Modifications -- 3.5.4 Drug Resistance and Programmed Cell Death -- 3.6 RNA Interference Therapy -- 3.7 Methods of Physical Intervention to Treat MDR -- 3.8 Conclusion -- References -- Chapter 4 Natural Products for Clinical Management of Drug Resistant Cancer Cells -- 4.1 Introduction -- 4.2 Resistance Mechanisms -- 4.3 Antitumor Plants for Multi-Drug-Resistant Cells -- 4.4 Qualea Species and Their Medical Applications -- 4.5 Antitumor Activity of Qualea Grandiflora and Qualea Multiflora -- 4.6 Conclusion -- References -- Chapter 5 Understanding of Autophagy to Combat MDR During Anticancer Therapy -- 5.1 Introduction -- 5.2 Mechanisms of Autophagy -- 5.2.1 Phagophore Assembly -- 5.2.2 Autophagosome Formation and Maturation -- 5.2.3 Autolysosome Degradation -- 5.2.4 Core Regulator of Autophagy -- 5.3 Mechanisms of MDR -- 5.4 Correlation Between Autophagy and Multi-Drug Resistance -- 5.5 The Cytoprotective Effect of Autophagy in the Regulation of Multi-Drug Resistance -- 5.6 Increased Autophagy Facilitates Multi-Drug Resistance -- 5.7 Autophagy Inhibition Improves Chemotherapy in MDR Cancers -- 5.8 Overcoming MDR With Autophagic Cell Death -- 5.9 Autophagy Kills Apoptosis-Deficient MDR Cancer Cells -- 5.10 Autophagy Promotes Chemosensitivity -- 5.11 Conclusion -- References -- Chapter 6 Transporter Inhibitors: A Chemotherapeutic Regimen to Improve the Clinical Outcome of Colorectal Cancer -- 6.1 Introduction -- 6.2 CRC Transporters or ATP-Binding Cassette -- 6.2.1 ABC Transporter Family -- 6.2.2 ABC Transporters and CRC Initiation -- 6.2.3 ABC Transporters and the Resistance of Cancer Cells to Chemotherapy. 6.3 Clinical Evidence for the Function of ABC Transporters in CRC MDR -- 6.3.1 Intrinsic Drug Resistance in Colon Cancer Upregulation of P-gp at Detection -- 6.3.2 Proliferating Tumor Cells Have MRP1 on Their Surface -- 6.4 General Approaches -- 6.5 By Blocking Tyrosine Kinase Inhibitors from Inhibiting MDR Transporters -- 6.6 Components Produced from Natural Sources that Inhibit MDR Transporters -- 6.7 Inhibiting ABC Transporters in Other Ways for CRC MDR Circumvention -- 6.8 Challenges and Future Prospective -- 6.9 Conclusion -- References -- Chapter 7 Epithelial to Mesenchymal Transition (EMT): Major Contribution to Cancer Drug Therapy Resistance -- 7.1 Introduction -- 7.2 EMT and Tumor Resistance: In Vitro, In Vivo, and Clinical Trials -- 7.3 Tumor Microenvironment Regulates EMT -- 7.3.1 Hypoxia -- 7.3.2 The Extracellular Matrix -- 7.3.3 The Inflammatory and Immune Microenvironment -- 7.3.4 EMT Microenvironment: Medication Resistance -- 7.4 Drug Resistance and EMT Bioinformatics -- 7.4.1 Bioinformatics and Pharmacogenomics to Optimize Drugs and Targets and Identify Medication Resistance -- 7.4.2 Drug Resistance: Hereditary or Acquired -- 7.4.3 Therapies for EMT-Induced Medication Resistance -- 7.5 Conclusion -- References -- Chapter 8 Advances in Metallodrug-Driven Combination Therapy for Treatment of Cancer -- 8.1 Introduction -- 8.2 Cancer Treatment Using Combination Therapy -- 8.3 Combined Treatment with Metallodrugs for Cancer Treatment -- 8.3.1 Platinum Metallodrugs -- 8.4 Nonplatinum Metallodrugs -- 8.5 Conclusion -- References -- Chapter 9 Novel Strategies Preventing Emergence of MDR in Breast Cancer -- 9.1 Introduction -- 9.2 Breast Cancer Categorization and Epidemiological Studies -- 9.2.1 Treatment Options for Women With Breast Cancer -- 9.3 Multi-Drug Resistance in Breast Cancer -- 9.3.1 Breast Cancer Chemoresistance. 9.3.2 Multi-Drug Resistance and ABC Channels in Breast Cancer -- 9.4 Drug Efflux Transporters in Breast Cancer -- 9.4.1 Exocytosis Transporters in the Stem Cell Population of Breast Cancer -- 9.4.2 Drug Efflux Channel Upregulation in Breast Cancer -- 9.4.3 Techniques for Breast Cancer MDR Reversal -- 9.4.4 Direct Pharmacologic Inhibition With MDR Inhibitors -- 9.5 Excessive Synthesis or Overexpression of Transporters for the Expulsion of Drugs -- 9.6 Nanotherapeutic Approach for MDR Reversal -- 9.7 Breast Cancer's MDR Cure Problems and Future Outlook -- 9.8 Conclusion -- References -- Index -- EULA. |
| Record Nr. | UNINA-9910830428803321 |
| Hoboken, NJ : , : John Wiley & Sons, , [2023] | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Neuroimaging pharmacopoeia / / editors, Daniel Thomas Ginat, Juan E. Small, Pamela W. Schaefer
| Neuroimaging pharmacopoeia / / editors, Daniel Thomas Ginat, Juan E. Small, Pamela W. Schaefer |
| Edizione | [Second edition.] |
| Pubbl/distr/stampa | Cham, Switzerland : , : Springer, , 2022 |
| Descrizione fisica | 1 online resource (413 pages) |
| Disciplina | 616.804754 |
| Soggetto topico |
Brain - Imaging
Drug interactions |
| ISBN | 3-031-08774-7 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Intro -- Contents -- Part I: Drugs and Alcohol -- 1: Tobacco -- 1.1 Uses -- 1.2 Mechanism -- 1.3 Imaging Findings -- 1.3.1 Stroke -- 1.3.2 Cerebral Aneurysm -- 1.3.3 Cerebral Venous Thrombosis -- 1.3.4 Head and Neck Cancer, Squamous Cell Carcinoma -- 1.3.5 Brain Metastases -- 1.3.6 Warthin Tumor -- 1.3.7 Smoking-Induced Nasopharyngeal Lymphoid Hyperplasia -- Suggested Reading -- 2: Alcohol -- 2.1 Uses -- 2.2 Mechanism -- 2.3 Imaging Findings -- Suggested Reading -- 3: Methanol -- 3.1 Uses -- 3.2 Mechanism -- 3.3 Imaging Findings -- 3.4 Differential Diagnosis -- Suggested Reading -- 4: Cannabis (Marijuana) -- 4.1 Uses -- 4.2 Mechanism -- 4.3 Imaging Findings -- 4.4 Differential Diagnosis -- Suggested Reading -- 5: Synthetic Cannabinoids -- 5.1 Uses -- 5.2 Mechanism -- 5.3 Imaging Findings -- 5.4 Differential Diagnosis -- Suggested Reading -- 6: Crack and Cocaine -- 6.1 Uses -- 6.2 Mechanism -- 6.3 Imaging Findings -- 6.4 Differential Diagnosis -- Suggested Reading -- 7: Amphetamines -- 7.1 Uses -- 7.2 Mechanism -- 7.3 Imaging Findings -- 7.4 Differential Diagnosis -- Suggested Reading -- 8: Opioids -- 8.1 Uses -- 8.2 Mechanism -- 8.3 Imaging Findings -- 8.4 Differential Diagnosis -- Suggested Reading -- 9: Betel Nuts -- 9.1 Uses -- 9.2 Mechanism -- 9.3 Imaging Findings -- 9.4 Differential Diagnosis -- Suggested Reading -- 10: Licorice -- 10.1 Uses -- 10.2 Mechanism -- 10.3 Imaging Findings -- 10.4 Differential Diagnosis -- Suggested Reading -- 11: Centella asiatica -- 11.1 Uses -- 11.2 Mechanism -- 11.3 Imaging Findings -- 11.4 Differential Diagnosis -- Suggested Reading -- Part II: Contrast Agents -- 12: Iodinated Contrast Agents -- 12.1 Uses -- 12.2 Mechanism -- 12.3 Imaging Findings -- 12.4 Differential Diagnosis -- Suggested Reading -- 13: Gadolinium-Based Contrast Agents -- 13.1 Uses.
13.2 Mechanism -- 13.3 Imaging Findings -- 13.4 Differential Diagnosis -- Suggested Reading -- 14: Ferumoxytol -- 14.1 Uses -- 14.2 Mechanism of Action -- 14.3 Imaging Findings -- 14.4 Differential Diagnosis -- Suggested Reading -- 15: Pantopaque (Myodil, Iodophenylundecylic Acid) -- 15.1 Uses -- 15.2 Mechanism -- 15.3 Imaging Findings -- 15.4 Differential Diagnosis -- Suggested Reading -- 16: Thorium Dioxide (Thorotrast) -- 16.1 Uses -- 16.2 Mechanism -- 16.3 Imaging Findings -- 16.4 Differential Diagnosis -- Suggested Reading -- Part III: Chemotherapy -- 17: Temozolamide (Temodar) -- 17.1 Uses -- 17.2 Mechanism -- 17.3 Imaging Findings -- 17.4 Differential Diagnosis -- Suggested Reading -- 18: 1,3-Bis(2-Chloroethyl)-1-Nitrosourea (BCNU -- Carmustine) Polymer Wafer (Gliadel) -- 18.1 Uses -- 18.2 Mechanism -- 18.3 Imaging Findings -- 18.4 Differential Diagnosis -- Suggested Reading -- 19: Methotrexate -- 19.1 Uses -- 19.2 Mechanism -- 19.3 Imaging Findings -- 19.4 Differential Diagnosis -- Suggested Reading -- 20: 5-Fluorouracil -- 20.1 Uses -- 20.2 Mechanism -- 20.3 Imaging Findings -- 20.4 Differential Diagnosis -- Suggested Reading -- 21: l-Asparaginase (Elspar/Erwinase) -- 21.1 Uses -- 21.2 Mechanism -- 21.3 Imaging Findings -- 21.4 Differential Diagnosis -- Suggested Reading -- 22: Calcineurin Inhibitors -- 22.1 Uses -- 22.2 Mechanism -- 22.3 Imaging Findings -- 22.4 Differential Diagnosis -- Suggested Reading -- 23: Bromocriptine (Parlodel) and Cabergoline (Dostinex) -- 23.1 Uses -- 23.2 Mechanism -- 23.3 Imaging Findings -- 23.4 Differential Diagnosis -- Suggested Reading -- 24: HiDAC (High-Dose Ara-C -- Cytarabine -- Cytosine Arabinoside -- Cytosar-U -- Depocyt) -- 24.1 Uses -- 24.2 Mechanism -- 24.3 Imaging Findings -- 24.4 Differential Diagnosis -- Suggested Reading. Part IV: Anti-Cancer Immunotherapy -- 25: Ipilimumab (MDX-010, Yervoy) -- 25.1 Uses -- 25.2 Mechanism -- 25.3 Imaging Findings -- 25.4 Differential Diagnosis -- Suggested Reading -- 26: Bevacizumab (Avastin) -- 26.1 Uses -- 26.2 Mechanism -- 26.3 Imaging Findings -- 26.4 Differential Diagnosis -- Suggested Reading -- 27: Chimeric Antigen Receptor T-Cell Therapy (Tisagenlecleucel and Axicabtagene Ciloleucel) -- 27.1 Uses -- 27.2 Mechanism -- 27.3 Imaging Findings -- 27.4 Differential Diagnosis -- Suggested Reading -- Part V: Antibiotics, Antiviral Agents, and Vaccines -- 28: Metronidazole (Flagyl) -- 28.1 Uses -- 28.2 Mechanism -- 28.3 Imaging Findings -- 28.4 Differential Diagnosis -- Suggested Reading -- 29: Iodoform -- 29.1 Uses -- 29.2 Mechanism -- 29.3 Imaging Findings -- 29.4 Differential Diagnosis -- Suggested Reading -- 30: Isoniazid -- 30.1 Uses -- 30.2 Mechanism -- 30.3 Imaging Findings -- 30.4 Differential Diagnosis -- Suggested Reading -- 31: Highly Active Antiretroviral Therapy (HAART) -- 31.1 Uses -- 31.2 Mechanism -- 31.3 Imaging Findings -- 31.4 Differential Diagnosis -- Suggested Reading -- 32: Vaccines -- 32.1 Uses -- 32.2 Mechanism -- 32.3 Discussion -- 32.4 Differential Diagnosis -- Suggested Reading -- Part VI: Antiepilectic, Antipsychotic, and General Anesthetic Agents -- 33: Dilantin (Phenytoin Sodium) -- 33.1 Uses -- 33.2 Mechanism -- 33.3 Imaging Findings -- 33.4 Differential Diagnosis -- Suggested Reading -- 34: Valproic Acid (Sodium Valproate, Depakote) -- 34.1 Uses -- 34.2 Mechanism -- 34.3 Imaging Findings -- 34.4 Differential Diagnosis -- Suggested Reading -- 35: Vigabatrin (Sabril) -- 35.1 Uses -- 35.2 Mechanism -- 35.3 Imaging Findings -- 35.4 Differential Diagnosis -- Suggested Reading -- 36: Lithium -- 36.1 Uses -- 36.2 Mechanism -- 36.3 Imaging Findings. 36.4 Differential Diagnosis -- Suggested Reading -- 37: Neuroleptics -- 37.1 Uses -- 37.2 Mechanism -- 37.3 Imaging Findings -- 37.4 Differential Diagnosis -- Suggested Reading -- Part VII: Anesthetic and Sedative Agents -- 38: Barbiturates (Pentobarbital) -- 38.1 Uses -- 38.2 Mechanism -- 38.3 Imaging Findings -- Suggested Reading -- 39: Nitrous Oxide (N2O) -- 39.1 Uses -- 39.2 Mechanism -- 39.3 Imaging Findings -- 39.4 Differential Diagnosis -- Suggested Reading -- 40: Propofol -- 40.1 Uses -- 40.2 Mechanism -- 40.3 Imaging Findings -- 40.4 Differential Diagnosis -- Suggested Reading -- Part VIII: Hemostatic and Vasoactive Agents -- 41: Embolic Agents -- 41.1 Uses -- 41.2 Mechanism -- 41.3 Imaging Findings -- 41.4 Differential Diagnosis -- Suggested Reading -- 42: Aspirin and Plavix/Clopidogrel -- 42.1 Uses -- 42.2 Mechanism -- 42.3 Imaging Findings -- 42.4 Differential Diagnosis -- Suggested Reading -- 43: Warfarin (Coumadin) -- 43.1 Uses -- 43.2 Mechanism -- 43.3 Imaging Findings -- 43.4 Differential Diagnosis -- Suggested Reading -- 44: Heparin -- 44.1 Uses -- 44.2 Mechanism -- 44.3 Imaging Findings -- 44.4 Differential Diagnosis -- Suggested Reading -- 45: Tissue Plasminogen Activator (tPA) -- 45.1 Uses -- 45.2 Mechanism -- 45.3 Imaging Findings -- 45.4 Differential Diagnosis -- Suggested Reading -- 46: Oxidized Cellulose -- 46.1 Uses -- 46.2 Mechanism -- 46.3 Imaging Findings -- 46.4 Differential Diagnosis -- Suggested Reading -- 47: Nasal Decongestants -- 47.1 Uses -- 47.2 Mechanism -- 47.3 Imaging Findings -- 47.4 Differential Diagnosis -- Suggested Reading -- Part IX: Cardiovascular Support Agents -- 48: Supplemental Oxygen -- 48.1 Uses -- 48.2 Mechanism -- 48.3 Imaging Findings -- 48.4 Differential Diagnosis -- Suggested Reading -- 49: Hypertonic Saline -- 49.1 Uses -- 49.2 Mechanism. 49.3 Imaging Findings -- 49.4 Differential Diagnosis -- Suggested Reading -- 50: Mannitol (1,2,3,4,5, 6-Hexanehexol) -- 50.1 Uses -- 50.2 Mechanism -- 50.3 Imaging Findings -- 50.4 Differential Diagnosis -- Suggested Reading -- 51: Triple H Therapy -- 51.1 Uses -- 51.2 Mechanism -- 51.3 Imaging Findings -- 51.4 Differential Diagnosis -- Suggested Reading -- 52: Angiotensin-Converting Enzyme (ACE) Inhibitors -- 52.1 Uses -- 52.2 Mechanism -- 52.3 Imaging Findings -- 52.4 Differential Diagnosis -- Suggested Reading -- 53: Acetazolamide (Diamox) -- 53.1 Uses -- 53.2 Mechanism -- 53.3 Imaging Findings -- 53.4 Differential Diagnosis -- Suggested Reading -- 54: Amiodarone -- 54.1 Uses -- 54.2 Mechanism -- 54.3 Imaging Findings -- 54.4 Differential Diagnosis -- Suggested Reading -- Part X: Anti-Inflammatory Agents -- 55: Acetominophen (Tylenol, Paracetamol) -- 55.1 Uses -- 55.2 Mechanism -- 55.3 Imaging Findings -- 55.4 Differential Diagnosis -- Suggested Reading -- 56: Natalizumab (Tysabri, Biogen Idec and Elan Pharmaceuticals) -- 56.1 Uses -- 56.2 Mechanism -- 56.3 Imaging Findings -- 56.4 Differential Diagnosis -- Suggested Reading -- 57: Synthetic Corticosteroids -- 57.1 Uses -- 57.2 Mechanism -- 57.3 Imaging Findings -- 57.4 Differential Diagnosis -- Suggested Reading -- Part XI: Dietary Supplements, Homeostatic Agents, and Hormone-Like Drugs -- 58: Manganese in Total Parenteral Nutrition -- 58.1 Uses -- 58.2 Mechanism -- 58.3 Imaging Findings -- 58.4 Differential Diagnosis -- Suggested Reading -- 59: Zinc Oxide (ZnO) -- 59.1 Uses -- 59.2 Mechanism -- 59.3 Imaging Findings -- 59.4 Differential Diagnosis -- Suggested Reading -- 60: Insulin -- 60.1 Uses -- 60.2 Mechanism -- 60.3 Imaging Findings -- 60.4 Differential diagnosis -- Suggested Reading -- 61: Bisphosphonates -- 61.1 Uses -- 61.2 Mechanism. 61.3 Imaging Findings. |
| Record Nr. | UNINA-9910633917403321 |
| Cham, Switzerland : , : Springer, , 2022 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Reactions weekly
| Reactions weekly |
| Pubbl/distr/stampa | Auckland, N.Z., : ADIS International, 1990- |
| Descrizione fisica | 1 online resource (v.) |
| Soggetto topico |
Drugs - Side effects
Drug interactions Drugs - Toxicology Drug Interactions Drug-Related Side Effects and Adverse Reactions Substance-Related Disorders Médicaments - Interactions Médicaments - Effets secondaires Electronic journals |
| Soggetto genere / forma |
Periodicals.
Periodical |
| ISSN | 1179-2051 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNISA-996199578403316 |
| Auckland, N.Z., : ADIS International, 1990- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
Reactions weekly
| Reactions weekly |
| Pubbl/distr/stampa | Auckland, N.Z., : ADIS International, 1990- |
| Descrizione fisica | 1 online resource (v.) |
| Soggetto topico |
Drugs - Side effects
Drug interactions Drugs - Toxicology Drug Interactions Drug-Related Side Effects and Adverse Reactions Substance-Related Disorders Médicaments - Interactions Médicaments - Effets secondaires Electronic journals |
| Soggetto genere / forma |
Periodicals.
Periodical |
| ISSN | 1179-2051 |
| Formato | Materiale a stampa |
| Livello bibliografico | Periodico |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910482002603321 |
| Auckland, N.Z., : ADIS International, 1990- | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
